FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148644571> ?p ?o ?g. }

• W2148644571 endingPage "1402" @default.
• W2148644571 startingPage "1396" @default.
• W2148644571 abstract "M3 subtype muscarinic receptors (CHRM3) are over-expressed in colon cancer. In this study, we used Apc(min/+) mice to identify the role of Chrm3 expression in a genetic model of intestinal neoplasia, explored the role of Chrm3 in intestinal mucosal development and determined the translational potential of inhibiting muscarinic receptor activation. We generated Chrm3-deficient Apc(min/+) mice and compared intestinal morphology and tumor number in 12-week-old Apc(min/+)Chrm3(-/-) and Apc(min/+)Chrm3(+/+) control mice. Compared with Apc(min/+)Chrm3(+/+) mice, Apc(min/+)Chrm3(-/-) mice showed a 70 and 81% reduction in tumor number and volume, respectively (P < 0.01). In adenomas, β-catenin nuclear staining was reduced in Apc(min/+)Chrm3(-/-) compared with Apc(min/+)Chrm3(+/+) mice (P < 0.02). Whereas Apc gene mutation increased the number of crypt and Paneth cells and decreased villus goblet cells, these changes were absent in Apc(min/+)Chrm3(-/-) mice. To determine whether pharmacological inhibition of muscarinic receptor activation attenuates intestinal neoplasia, we treated 6-week-old Apc(min/+) mice with scopolamine butylbromide, a non-subtype-selective muscarinic receptor antagonist. After 8 weeks of continuous treatment, scopolamine butylbromide-treated mice showed a 22% reduction in tumor number (P = 0.027) and a 36% reduction in tumor volume (P = 0.004) as compared with control mice. Compared with Chrm3 gene ablation, the muscarinic antagonist was less efficacious, most probably due to shorter duration of treatment and incomplete blockade of muscarinic receptors. Overall, these findings indicate that interplay of Chrm3 and β-catenin signaling is important for intestinal mucosal differentiation and neoplasia and provide a proof-of-concept that pharmacological inhibition of muscarinic receptor activation can attenuate intestinal neoplasia in vivo." @default.
• W2148644571 created "2016-06-24" @default.
• W2148644571 creator A5002283703 @default.
• W2148644571 creator A5003132973 @default.
• W2148644571 creator A5012287827 @default.
• W2148644571 creator A5015095365 @default.
• W2148644571 creator A5016410787 @default.
• W2148644571 creator A5024672963 @default.
• W2148644571 creator A5024756104 @default.
• W2148644571 creator A5034515120 @default.
• W2148644571 creator A5036533621 @default.
• W2148644571 creator A5052026371 @default.
• W2148644571 creator A5060948677 @default.
• W2148644571 date "2011-06-24" @default.
• W2148644571 modified "2023-10-12" @default.
• W2148644571 title "Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice" @default.
• W2148644571 cites W1980856647 @default.
• W2148644571 cites W1990499122 @default.
• W2148644571 cites W1992127683 @default.
• W2148644571 cites W1993748871 @default.
• W2148644571 cites W1999197325 @default.
• W2148644571 cites W2006126215 @default.
• W2148644571 cites W2014784259 @default.
• W2148644571 cites W2016789358 @default.
• W2148644571 cites W2029253392 @default.
• W2148644571 cites W2034373020 @default.
• W2148644571 cites W2053140711 @default.
• W2148644571 cites W2072110539 @default.
• W2148644571 cites W2077366285 @default.
• W2148644571 cites W2084662944 @default.
• W2148644571 cites W2105131345 @default.
• W2148644571 cites W2117788878 @default.
• W2148644571 cites W2135854450 @default.
• W2148644571 cites W2139264419 @default.
• W2148644571 cites W2153975978 @default.
• W2148644571 cites W2160169458 @default.
• W2148644571 cites W2168048525 @default.
• W2148644571 cites W2169520297 @default.
• W2148644571 doi "https://doi.org/10.1093/carcin/bgr118" @default.
• W2148644571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3165126" @default.
• W2148644571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21705482" @default.
• W2148644571 hasPublicationYear "2011" @default.
• W2148644571 type Work @default.
• W2148644571 sameAs 2148644571 @default.
• W2148644571 citedByCount "56" @default.
• W2148644571 countsByYear W21486445712012 @default.
• W2148644571 countsByYear W21486445712013 @default.
• W2148644571 countsByYear W21486445712014 @default.
• W2148644571 countsByYear W21486445712015 @default.
• W2148644571 countsByYear W21486445712016 @default.
• W2148644571 countsByYear W21486445712017 @default.
• W2148644571 countsByYear W21486445712018 @default.
• W2148644571 countsByYear W21486445712019 @default.
• W2148644571 countsByYear W21486445712020 @default.
• W2148644571 countsByYear W21486445712021 @default.
• W2148644571 countsByYear W21486445712022 @default.
• W2148644571 countsByYear W21486445712023 @default.
• W2148644571 crossrefType "journal-article" @default.
• W2148644571 hasAuthorship W2148644571A5002283703 @default.
• W2148644571 hasAuthorship W2148644571A5003132973 @default.
• W2148644571 hasAuthorship W2148644571A5012287827 @default.
• W2148644571 hasAuthorship W2148644571A5015095365 @default.
• W2148644571 hasAuthorship W2148644571A5016410787 @default.
• W2148644571 hasAuthorship W2148644571A5024672963 @default.
• W2148644571 hasAuthorship W2148644571A5024756104 @default.
• W2148644571 hasAuthorship W2148644571A5034515120 @default.
• W2148644571 hasAuthorship W2148644571A5036533621 @default.
• W2148644571 hasAuthorship W2148644571A5052026371 @default.
• W2148644571 hasAuthorship W2148644571A5060948677 @default.
• W2148644571 hasBestOaLocation W21486445711 @default.
• W2148644571 hasConcept C116289061 @default.
• W2148644571 hasConcept C126322002 @default.
• W2148644571 hasConcept C134018914 @default.
• W2148644571 hasConcept C170493617 @default.
• W2148644571 hasConcept C33789571 @default.
• W2148644571 hasConcept C71924100 @default.
• W2148644571 hasConcept C86803240 @default.
• W2148644571 hasConceptScore W2148644571C116289061 @default.
• W2148644571 hasConceptScore W2148644571C126322002 @default.
• W2148644571 hasConceptScore W2148644571C134018914 @default.
• W2148644571 hasConceptScore W2148644571C170493617 @default.
• W2148644571 hasConceptScore W2148644571C33789571 @default.
• W2148644571 hasConceptScore W2148644571C71924100 @default.
• W2148644571 hasConceptScore W2148644571C86803240 @default.
• W2148644571 hasIssue "9" @default.
• W2148644571 hasLocation W21486445711 @default.
• W2148644571 hasLocation W21486445712 @default.
• W2148644571 hasLocation W21486445713 @default.
• W2148644571 hasLocation W21486445714 @default.
• W2148644571 hasOpenAccess W2148644571 @default.
• W2148644571 hasPrimaryLocation W21486445711 @default.
• W2148644571 hasRelatedWork W1970289512 @default.
• W2148644571 hasRelatedWork W2018368842 @default.
• W2148644571 hasRelatedWork W2033472167 @default.
• W2148644571 hasRelatedWork W2034583712 @default.
• W2148644571 hasRelatedWork W2050559793 @default.
• W2148644571 hasRelatedWork W2063619316 @default.
• W2148644571 hasRelatedWork W2094064741 @default.

• next